Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity.

Gaucher disease is a lysosomal storage disorder characterized by a deficiency of the enzyme acid beta-glucosidase. The clinical manifestations of Gaucher disease are highly variable, and although certain genotypes are often associated with mild or severe symptoms, a defined correlation between genotype and phenotype does not exist. Identification of biochemical markers characteristic of pathology may be of use in predicting the progression of the disease state. In this study the relationship among genotype, glycolipid substrates, lysosomal proteins, and the clinical manifestations of Gaucher disease has been evaluated. Plasma glycolipids were analyzed using electrospray ionization-tandem mass spectrometry. Lysosomal-associated membrane protein-1 (LAMP-1) and saposin C were determined by immunoquantification. Patients with Gaucher disease were shown to have an increased 16:0-glucosylceramide/16:0-lactosylceramide ratio and elevated concentrations of LAMP-1 and saposin C in plasma. A general relationship was found to exist among the 16:0-glucosylceramide/16:0-lactosylceramide ratio, LAMP-1 and saposin C levels, and patient phenotype, providing a refinement of the genotype-phenotype correlation. These findings have major implications for the diagnosis, prediction of disease severity, and monitoring of therapy in patients with Gaucher disease.

[1]  W. Swaney,et al.  Gene Transfer Approaches to the Lysosomal Storage Disorders , 1999, Neurochemical Research.

[2]  E R McCabe,et al.  Consequences of complexity within biological networks: robustness and health, or vulnerability and disease. , 2001, Molecular genetics and metabolism.

[3]  E. McCabe,et al.  Modifier genes convert "simple" Mendelian disorders to complex traits. , 2000, Molecular genetics and metabolism.

[4]  J. K. Park,et al.  Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. , 2000, American journal of human genetics.

[5]  E R McCabe,et al.  Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. , 2000, American journal of human genetics.

[6]  R. Dwek,et al.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis , 2000, The Lancet.

[7]  J. Christodoulou,et al.  Type 2 Gaucher disease: the collodion baby phenotype revisited , 2000, Archives of disease in childhood. Fetal and neonatal edition.

[8]  P. Meikle,et al.  Saposins A, B, C, and D in plasma of patients with lysosomal storage disorders. , 2000, Clinical chemistry.

[9]  H. Naim,et al.  Intracellular transport of acid β‐glucosidase and lysosome‐associated membrane proteins is affected in Gaucher's disease (G202R mutation) , 1999, The Journal of pathology.

[10]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[11]  P. Meikle,et al.  Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker. , 1997, Clinical chemistry.

[12]  E. Levy-Lahad,et al.  Replacement therapy with imiglucerase for type 1 Gaucher's disease , 1995, The Lancet.

[13]  D. Frappaz,et al.  Allogeneic bone marrow transplantation for lysosomal storage diseases , 1995, The Lancet.

[14]  K. Beckman,et al.  Very long chain fatty acids in X‐linked adrenoleukodystrophy brain after treatment with Lorenzo's oil , 1994, Annals of neurology.

[15]  C. Hollak,et al.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. , 1994, The Journal of clinical investigation.

[16]  C. P. Morris,et al.  Mutation analysis of 28 Gaucher disease patients: the Australasian experience. , 1994, American journal of medical genetics.

[17]  J. Goldblatt,et al.  Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. , 1991, Biochimica et biophysica acta.

[18]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[19]  P. Strasberg,et al.  HPLC analysis of neutral glycolipids: an aid in the diagnosis of lysosomal storage disease. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[20]  C. Groth,et al.  Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: Significant differences between Type I and Type III , 1982, Clinical Genetics.

[21]  S. Roth,et al.  A protein activator of galactosylceramide β-galactosidase , 1982 .

[22]  H. Moser,et al.  Application of "high-performance" liquid chromatography to the study of sphingolipidoses. , 1980, Clinical chemistry.

[23]  M. David,et al.  Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of their perbenzoyl derivatives. , 1977, Journal of lipid research.

[24]  J. Oh,et al.  Blood glucosylceramide levels in Gaucher's disease and its distribution amongst lipoprotein fractions. , 1977, Clinica chimica acta; international journal of clinical chemistry.

[25]  A. Poulos,et al.  A rapid method for the estimation of β-galacto-cerebrosidase, β-glucocerebrosidase and sphingomyelinase activities in leukocytes , 1976 .

[26]  H. Wells,et al.  Galactosylceramides in human plasma. , 1973, American journal of clinical pathology.

[27]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.